Q4 2024 MiMedx Group Inc Earnings Call Transcript
Key Points
- MiMedx Group Inc (MDXG) reported a 9% increase in full-year revenue for 2024, with Q4 net sales growing by 7% to $93 million.
- The company maintained a strong gross profit margin of 82% in Q4 and achieved an adjusted EBITDA of $20 million, representing 21% of sales.
- MiMedx Group Inc (MDXG) ended the year with $104 million in cash, an increase of $16 million during the quarter, highlighting strong cash flow generation.
- The company continued the market release of HELIOGEN, its first xenograft, and began enrollment for a randomized controlled trial for EPIEFFECT.
- MiMedx Group Inc (MDXG) experienced significant growth in its EPIFIX business in Japan, with sales nearly tripling in 2024.
- The company faced challenges due to Medicare reimbursement issues and above-average sales force turnover in select markets.
- Gross margin slightly decreased from 84% in the previous year to 82% in Q4 2024, partly due to acquisition-related amortization expenses.
- Selling, general, and administrative expenses increased to $61 million in Q4, up from $54 million in the prior year, primarily due to higher commissions and adjusted commission rates.
- Research and development expenses rose by 38% compared to the prior year, driven by increased costs associated with ongoing trials and future product development.
- The implementation of new Medicare reimbursement guidelines (LCDs) could lead to short-term market disruption and uncertainty in physician ordering patterns.
Good afternoon and thank you for standing by. Welcome to the MiMedx fourth-quarter and full-year 2024 operating financial results conference call.
(Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the call over to your host, Mr. Matt Notarianni, Head of Investor Relations for MiMedx. Thank you. You may begin.
Thank you, operator, and good afternoon, everyone. Welcome to the MiMedx fourth-quarter and full-year 2024 operating and financial results conference call.
With me on today's call are Chief Executive Officer, Joe Capper and Chief Financial Officer, Doug Rice. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at mimedx.com.
Joe will kick us off with some opening remarks and a summary of our operating highlights, and Doug will provide a review of our financial results for the quarter, and then Joe will conclude
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
